Effect And Analysis Of Recombinant Human Growth Hormone In Treatment Of Idiopathic Short Stature In Children

Objective: With the development of society and the improvement of national economy,people pay more and more attention to the pursuit of beauty.Because of the influence of short stature on children’s self-esteem,life and work,children with short stature and their families often have a strong need to improve their height.The causes of short stature include idiopathic short stature（ISS）,Growth hormone deficiency（GHD）,craniocerebral trauma,some hereditary diseases and endocrine disease.ISS is the commonest cause of short stature.Exogenous growth hormone supplementation is an effective way to treat children with idiopathic short stature.The aim of this study was to compare the efficacy and safety of Recombinant human growth hormone（rhGH）and Polyethylene glycol Recombinant human growth hormone（PEG-RHGH）in the treatment of height growth in children with short stature.Methods: A retrospective analysis of children with Idiopathic short stature was conducted from January 2018 to January 2021 at the China-Japan Union Hospital of Jilin University.A total of 148 idiopathic short stature patients were treated during the follow-up period of more than 12 months,including 96 cases of rhGH treatment and 52 cases of PEG-rhGH treatment.Height,height growth（△Ht）,growth velocity（GV）,thyroid function,Fasting blood glucose（FBG）,Insulin-like growth factor 1（IGF-1）,other indicators and adverse events in the two groups were observed to study and analyze the efficacy and safety of two different dosage forms of growth hormone.Results:1.Height after 12 months of treatment were higher than those after 6 months of treatment and higher than before treatment in both the PEG-rhGH and rhGH groups,and the difference was statistically significant（P < 0.05）.And height in the PEG-rhGH group were higher than those in the rhGH group at 6 months and 12 months of treatment,and the difference was statistically significant（P < 0.05）.2.GV at 7-12 months of treatment were higher than those at 0-6 months of treatment in both PEG-rhGH and rhGH groups,and the differences were statistically significant（P < 0.05）.GV in the PEG-rhGH group were higher than those in the rhGH group during the treatment,and the difference was statistically significant（P < 0.05）.3.△Ht at 7-12 months of treatment were higher than those at 0-6 months of treatment in both PEG-rhGH and rhGH groups,and the differences were statistically significant（P < 0.05）.△Ht in the PEG-rhGH group were higher than those in the rhGH group during the treatment,and the difference was statistically significant（P < 0.05）.4.IGF-1 after 12 months of treatment were higher than those after 6 months of treatment and higher than before treatment in both the PEG-rhGH and rhGH groups,and the difference was statistically significant（P < 0.05）.IGF-1 in the PEG-rhGH group were higher than those in the rhGH group at 6 months and 12 months of treatment,and the difference was statistically significant（P < 0.05）5.During PEG-rhGH or RHGH treatment for children with Idiopathic short stature,thyroid function were monitored for 12 months,and there was no significant difference in between-group comparison and within-group comparison.（P > 0.05）.6.During PEG-rhGH or RHGH treatment for children with Idiopathic short stature,fasting blood glucose were monitored for 12 months,and there was no significant difference in between-group comparison and within-group comparison.（P > 0.05）.7.The incidence of adverse reactions was 6.25% in the rhGH group and 5.76% in the PEG-rhGH group during treatment,and no serious adverse reactions occurred in both groups.Conclusion:1.Both PEG-rhGH and rhGH can improve the height of Idiopathic short stature children,while PEG-rhGH performs better in practice.2.For both rhGH and PEG-rhGH,the height benefit was better at 7 to 12 months of treatment than at 0 to 6 months.3.No serious adverse events occurred in ISS children during the treatment with rhGH,indicating good safety.